Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Bioscience (RCUS) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer’s immunosuppressive mechanisms. This page provides investors and researchers with timely updates on the company’s developments in immuno-oncology, including advancements in its ATP-adenosine pathway research.
Access the latest press releases, clinical trial milestones, and financial disclosures in one centralized hub. Track updates on therapeutic candidates spanning small molecules and biologics, partnership announcements, and regulatory progress. Our curated news collection ensures you stay informed about RCUS’s efforts to address unmet needs in lung, colorectal, and pancreatic cancers.
Bookmark this page for real-time insights into Arcus Bioscience’s R&D pipeline, strategic initiatives, and industry positioning. Check back regularly for verified updates directly from corporate communications and trusted financial sources.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to five new employees, totaling 126,200 shares at an exercise price of $41.39, the closing price on February 8, 2021. This move is part of the Company’s 2020 Inducement Plan, aimed at attracting talent. Arcus is focused on developing cancer therapies, with four molecules in clinical trials, including Etrumadenant and AB680. The company emphasizes its commitment to addressing significant unmet needs in oncology while leveraging a robust pipeline of innovative treatments.
Arcus Biosciences (NYSE:RCUS) announced that Gilead Sciences will increase its ownership stake in the company from approximately 13% to 19.5% by purchasing 5,650,000 shares at $39.00 each. This investment highlights the partnership's strength and supports the acceleration of Arcus's clinical development plans for its four clinical-stage molecules, including AB680 for metastatic pancreatic cancer. Following this financing, Arcus expects to fund its operations through at least 2023. The ongoing collaboration is crucial for developing next-generation cancer therapies.
Arcus Biosciences (NYSE:RCUS) announced the grant of stock options to five new employees, totaling 165,300 shares at an exercise price of $38.19, based on the January 25, 2021 closing price. This grant was made under the 2020 Inducement Plan approved by the Board of Directors. The company focuses on developing innovative oncology therapies with four clinical-stage molecules, including Etrumadenant, AB680, Domvanalimab, and Zimberelimab, targeting various cancer types, illustrating its commitment to addressing significant unmet medical needs in oncology.
Arcus Biosciences (NYSE:RCUS) presented preliminary data from the ARC-8 Phase 1/1b study at ASCO 2021, focusing on the safety and efficacy of AB680, a small-molecule CD73 inhibitor, in metastatic pancreatic cancer. The study involved 19 patients receiving AB680, nab-paclitaxel, and gemcitabine. No significant additive toxicity was observed, although one patient experienced Grade 2 autoimmune hepatitis. Preliminary efficacy showed that 88% of patients had lesion shrinkage, with an overall response rate of 41%. AB680 was selected for expansion at 100mg every two weeks, showing potential for advancing treatment in this challenging cancer type.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options for 31,600 shares to three new employees, priced at $30.83 each, reflecting the company's closing share price on January 8, 2021. This initiative is part of the Company’s 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies, with four clinical candidates under evaluation for various cancer types, including the dual A2a/A2b antagonist, Etrumadenant, currently in multiple Phase 2 and 1b studies.
Arcus Biosciences (NYSE:RCUS) announced promising preliminary data from its ongoing Phase 1/1b trial, ARC-8, evaluating AB680 combined with zimberelimab and chemotherapy for front-line treatment of metastatic pancreatic cancer. The data shows favorable safety and clinical activity, indicating it is well-tolerated with side effects similar to established therapies. The company plans to present detailed results at the ASCO GI symposium on January 15, 2021, and advance to the Phase 1b expansion of the study.
Arcus Biosciences (NYSE:RCUS) announced the appointment of Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. to its Board of Directors, focusing on strengthening its leadership as it approaches a pivotal year with key clinical trials. Dr. Perlman, an experienced biotechnology leader, has played significant roles at Genentech and Tularik, while Dr. Quigley has a strong background in oncology drug discovery from Gilead and Bristol-Myers Squibb. Their expertise aims to enhance Arcus's strategy to maximize long-term value for patients and shareholders.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted stock options to 20 new employees, totaling 310,500 shares at an exercise price of $29.93. This grant adheres to the 2020 Inducement Plan, approved by the Board of Directors in January 2020, in compliance with NYSE rules. The company is focused on developing advanced therapies for cancer, with four clinical candidates currently under investigation. Etrumadenant, AB680, Domvanalimab, and Zimberelimab represent their innovative approach to addressing unmet medical needs in oncology.
Arcus Biosciences (RCUS) and WuXi Biologics have expanded their strategic partnership to discover anti-CD39 antibodies using WuXi's proprietary technology. This collaboration marks the fourth antibody development program between the two companies. Arcus has exclusive global rights to these antibodies and will handle further development and commercialization. The CD39 axis is critical for tumor immunosuppression, and preclinical data suggest that inhibiting CD39 may enhance anti-tumor immunity. Financial details of the agreement were not disclosed, and no material impact on Arcus’s financial position is anticipated.
Arcus Biosciences (NYSE:RCUS) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 10:30 a.m. Eastern Time. The event will feature a live audio webcast accessible via the Arcus website, with a replay available for two weeks post-event.
The company focuses on oncology and is advancing four clinical candidates: Etrumadenant (AB928), AB680, Domvanalimab (AB154), and Zimberelimab (AB122), targeting significant unmet needs in various cancers.
